Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication.

ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality and morbidity. Approval of antifibrotic therapy has ameliorated disease progression, but therapy response is heterogeneous and to date, adequate biomarkers predicting therapy response are lacking. In recent years metabolomic technology has improved and is broadly applied in cancer research thus enabling its use in other fields. Recently both aberrant metabolic and lipidomic pathways have been described to influence profibrotic responses. We thus aimed to characterize the metabolomic and lipidomic changes between IPF and healthy volunteers (HV) and analyze metabolomic changes following treatment with nintedanib and pirfenidone. We collected serial serum samples from two IPF cohorts from Germany (n

SUBMITTER: Seeliger B 

PROVIDER: S-EPMC9428132 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature